Eris Lifesciences Q4 FY26 results (Jan–Mar 2026) and concall

Healthcare · Concall AI · Call held 20 May 2026

Company page: Eris Lifesciences share price, financials & guidance record

Eris Lifesciences reported strong Q4 and FY26 results, driven by robust performance in Domestic Formulations, particularly the Insulin and Derma segments, and a successful Semaglutide launch. Despite regulatory delays impacting new product launches and international business, the company achieved significant PAT growth and maintained healthy margins. Management outlined plans for continued growth, margin improvement through insourcing, and resolution of regulatory observations.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q4 FY26: revenue down 31.6%, net profit down 130.0% against the same quarter last year.

₹ Cr · quarterly

Line item	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26
Revenue	400	405	579	650	315 −21%	277 −32%
Expenses	300	284	362	354	238	256
EBITDA	100	121	216	297	77 −23%	22 −82%
Margin	25%	30%	37%	46%	25%	8%
Other income	8	17	23	24	10	27
Interest	55	53	45	46	45	43
Depreciation	47	43	38	39	39	39
Profit before tax	6	41	156	235	4 −33%	-33 −180%
Tax rate	70%	26%	36%	36%	21%	-74%
Net profit	2	30	100	150	3 +50%	-9 −130%
EPS	0.13	2.24	7.34	10.98	0.23	-0.62

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Healthcare earnings calls